AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Trial: 24674827
Drug: Antibiotic prophylaxis
RxNorm normalized name: STONE PROPHYLAXIS
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Antibiotic prophylaxis with 1.0 g cefazolin intravenously 30 minutes before incision
Trial: 15117570
Drug: 0.1% pemirolast
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 0.1% pemirolast potassium ophthalmic solution dosed twice daily (b.i.d.)
Trial: 15117570
Drug: 0.1% pemirolast
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 0.1% pemirolast potassium ophthalmic solution dosed four times daily (q.i.d.)
Trial: 8129435
Drug: Ceftriaxone 100
RxNorm normalized name: ceftriaxone 1000 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Ceftriaxone 100 mg/kg intravenously followed by a single dose of 50 mg/kg 24 hours later
Trial: 8129435
Drug: Chloramphenicol 40
RxNorm normalized name: Chloramphenicol
DrugBank: Chloramphenicol succinate (DB07565)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Chloramphenicol 40 mg/kg intravenously, then 25 mg/kg eight hourly for five days
Trial: 379936
Drug: Levamisole (3
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Levamisole (3 days every 2 weeks, 1.1-3.8 mg/kg per day, fixed dose of 3 x 50 mg)
Trial: 16398702
Drug: NBI-6024 (five
FDA approved: no
EMA approved: no
PMDA approved: no
Description: NBI-6024 (five biweekly subcutaneous injections)
Trial: 1859293
Drug: Aspirin (exact
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Aspirin (exact dosage not specified)
Trial: 6643333
Drug: Intramuscular (im)
RxNorm normalized name: intramuscular immunoglobulin
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Intramuscular (im) administration of 500 mg
Trial: 6643333
Drug: Intravenous (iv)
RxNorm normalized name: intravenous (IV) infusion pump
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Intravenous (iv) administration of 500 mg
Trial: 24057039
Drug: Single-use injection
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Single-use injection device (SID)
Trial: 8078449
Drug: Nutrition therapy
RxNorm normalized name: Monistat Simple Therapy
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Nutrition therapy
Trial: 18394022
Drug: Simvastatin/Ezetimibe 10
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Simvastatin/Ezetimibe 10 mg/10 mg
Trial: 18394022
Drug: Both treatments
RxNorm normalized name: Hongo Killer Treatment
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Both treatments (Simvastatin and Simvastatin/Ezetimibe)
Trial: 9239452
Drug: Miglitol administered
RxNorm normalized name: Miglitol
DrugBank: Miglitol (DB00491)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Miglitol administered via intravenous route
Trial: 9239452
Drug: Miglitol administered
RxNorm normalized name: Miglitol
DrugBank: Miglitol (DB00491)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Miglitol administered via oral route
Trial: 9239452
Drug: Repeated administration
RxNorm normalized name: eicosyl povidone (2 eicosyl branches-repeat)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Repeated administration of miglitol to rats
Trial: 8452648
Drug: Combination pyrimethamine-sulfadiazine
RxNorm normalized name: pyrimethamine / sulfadiazine
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Combination pyrimethamine-sulfadiazine and spiramycine
Trial: 3777901
Drug: Low-dose ticarcillin
RxNorm normalized name: ethinyl estradiol
DrugBank: Ethinylestradiol (DB00977)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Low-dose ticarcillin (50 mg/kg)
Trial: 3777901
Drug: High-dose ticarcillin
FDA approved: no
EMA approved: no
PMDA approved: no
Description: High-dose ticarcillin (80 mg/kg)
Trial: 30327982
Drug: Intramuscular group
RxNorm normalized name: meningococcal group B vaccine Prefilled Syringe [Trumenba]
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Intramuscular group (IM)
Trial: 26910660
Drug: Perlane-L
RxNorm normalized name: Perlane
DrugBank: Hyaluronic acid (non-animal stabilized) (DB19175)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Perlane-L
Trial: 24927436
Drug: Probiotics administered
RxNorm normalized name: Rezyst Probiotic
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Probiotics administered from the day enteral feeding began
Trial: 22956296
Drug: Healthy lifestyles
RxNorm normalized name: Healthy Mama
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Healthy lifestyles intervention (Year 1: targeted home visits; Year 2: monthly newsletters and group meetings)
Trial: 22956296
Drug: Control (curricula
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Control (curricula materials during Year 1; monthly newsletters during Year 2)
Trial: 16319040
Drug: Intravenous magnesium
RxNorm normalized name: immunoglobulins, intravenous
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Intravenous magnesium (2 g IV Mg)
Trial: 8895675
Drug: Isolated liver
RxNorm normalized name: LIVER
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Isolated liver perfusion with 30 mg/m2 mitomycin C (MMC) recirculated for one hour
Trial: 8895675
Drug: Isolated liver
RxNorm normalized name: LIVER
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Isolated liver perfusion with 30 mg/m2 mitomycin C (MMC)
Trial: 1992381
Drug: Flunarizine (10
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Flunarizine (10 mg/d)
Trial: 6220895
Drug: Nifedipine (20
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Nifedipine (20 mg acute; 20 mg q.i.d. for 1 month)
Trial: 6220895
Drug: Verapamil (160
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Verapamil (160 mg acute; 160 mg t.i.d. for 1 month)
Trial: 30824336
Drug: DMET (1
FDA approved: no
EMA approved: no
PMDA approved: no
Description: DMET (1 mg/kg delivered over 10 minutes at the time of surgical closure)
Trial: 20694277
Drug: Enoxaparin (prophylactic
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Enoxaparin (prophylactic daily dose starting from positive pregnancy test)
Trial: 9003961
Drug: Active treatment
RxNorm normalized name: Activated Charcoal
DrugBank: Activated charcoal (DB09278)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Active treatment (transcranial electrostimulation)
Trial: 6735252
Drug: Indomethacin (75
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Indomethacin (75 mg sustained release capsules taken 12 and 24 hours before, and 50 mg taken one hour before histamine infusion)
Trial: 6735252
Drug: Matching placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Matching placebo capsules
Trial: 25387282
Drug: Lopinavir/ritonavir monotherapy
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Lopinavir/ritonavir monotherapy (LPV/r-MT) 400/100 mg BID
Trial: 25387282
Drug: Lopinavir/ritonavir monotherapy
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Lopinavir/ritonavir monotherapy (LPV/r-MT)
Trial: 12500989
Drug: Bovine colostrum
RxNorm normalized name: Bovine Colostrum
DrugBank: Bos taurus colostrum (DB19249)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Bovine colostrum (60 g daily)
Trial: 25833983
Drug: Whey protein
RxNorm normalized name: Whey protein
DrugBank: Whey (DB18685)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Whey protein (60 g daily)
Trial: 11966624
Drug: Mitomycin-C (40
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Mitomycin-C (40 mg)
Trial: 11966624
Drug: Interferon-alpha (all
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Interferon-alpha (all doses)
Trial: 9661606
Drug: Nal‐Glu GnRH
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Nal‐Glu GnRH antagonist (5, 15, 50, and 150 micrograms/kg)
Trial: 9661606
Drug: Nal‐Glu GnRH
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Nal‐Glu GnRH antagonist (150 micrograms/kg for 3-7 days)
Trial: 29554849
Drug: Dose-equivalent usual
RxNorm normalized name: HYDROGEN PEROXIDE 5 mg in 100 mL TOPICAL LIQUID [USUALKLENZ DISINFECTANTSPRAY]
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Dose-equivalent usual occupational therapy (DEUCC)
Trial: 29554849
Drug: Usual therapy
RxNorm normalized name: Monistat Simple Therapy
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Usual therapy (UCC)
Trial: 20528593
Drug: Inhaled fluticasone
RxNorm normalized name: fluticasone Inhalant Product
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Inhaled fluticasone propionate (FP; 400 microg/day)
Trial: 15786853
Drug: Exposed enrollees
RxNorm normalized name: lactose, x-ray exposed (1000 rad)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Exposed enrollees taking potentially contraindicated medications
Trial: 15786853
Drug: Unexposed enrollees
RxNorm normalized name: lactose, x-ray exposed (1000 rad)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Unexposed enrollees not taking potentially contraindicated medications
Trial: 14614228
Drug: Flutamide treatment
RxNorm normalized name: Flutamide
DrugBank: Flutamide (DB00499)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Flutamide treatment for 4 weeks
Trial: 1987737
Drug: Epirubicin (Epi)
DrugBank: Epirubicin (DB00445)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Epirubicin (Epi) 20 mg/m2 i.v. weekly
Trial: 1987737
Drug: Doxorubicin (Dox)
DrugBank: Doxorubicin (DB00997)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Doxorubicin (Dox) 20 mg/m2 i.v. weekly
Trial: 6307941
Drug: Prophylactic chemotherapy
RxNorm normalized name: polylactic acid-polyglycolic acid copolymer
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Prophylactic chemotherapy (cyclophosphamide and CCNU)
Trial: 6307941
Drug: Delayed chemotherapy
RxNorm normalized name: menthol
DrugBank: Menthol (DB14123)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Delayed chemotherapy (cyclophosphamide and CCNU)
Trial: 6307941
Drug: Thoracic irradiation
RxNorm normalized name: Thoracol
DrugBank: Menthol (DB14123)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Thoracic irradiation (TI), brain irradiation (BI), and early chemotherapy (CT)
Trial: 6307941
Drug: Thoracic irradiation
RxNorm normalized name: Thoracol
DrugBank: Menthol (DB14123)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Thoracic irradiation (TI) and chemotherapy (CT)
Trial: 29504254
Drug: Oral cholecalciferol
RxNorm normalized name: cholecalciferol Oral Capsule
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Oral cholecalciferol at 25,000 IU/wk
Trial: 27176725
Drug: Hydrogen water
RxNorm normalized name: Hydrogen
DrugBank: Hydrogen (DB15127)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Hydrogen water (1000 mL/day)
Trial: 12271348
Drug: Prompt L‐Pop
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Prompt L‐Pop (LP)
Trial: 9163011
Drug: Cisplatin administered
RxNorm normalized name: Cisplatin
DrugBank: Cisplatin (DB00515)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Cisplatin administered in the evening (Group A)
Trial: 9163011
Drug: Cisplatin administered
RxNorm normalized name: Cisplatin
DrugBank: Cisplatin (DB00515)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Cisplatin administered in the morning (Group B)
Trial: 1937374
Drug: 2 x
RxNorm normalized name: anti-HER2 x HER2 ADC
DrugBank: Zanidatamab zovodotin (DB15472)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 2 x 400 mg cimetidine daily for 10 days
Trial: 1937374
Drug: 2 x
RxNorm normalized name: anti-HER2 x HER2 ADC
DrugBank: Zanidatamab zovodotin (DB15472)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 2 x 400 mg cimetidine daily for 28 days
Trial: 7023678
Drug: Placebo (one
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Placebo (one tablet after lunch and one at bedtime)
Trial: 27355267
Drug: Insulin (standard
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Insulin (standard of care)
Trial: 18535027
Drug: Individualised rehabilitation
RxNorm normalized name: GLUTATHIONE 12.5 g in 100 mL ORAL LIQUID [K2LTS Brain Rehabilitation]
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Individualised rehabilitation programme (treatment group, n = 49)
Trial: 15992459
Drug: Zoledronic acid
RxNorm normalized name: Zoledronic Acid
DrugBank: Zoledronic acid (DB00399)
FDA approved: yes
EMA approved: yes
PMDA approved: no
Description: Zoledronic acid (4 mg every 3 weeks)
Trial: 10731304
Drug: Nedocromil sodium
RxNorm normalized name: Nedocromil Sodium
DrugBank: Nedocromil (DB00716)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Nedocromil sodium (4 mg) given 30 min or 3.5 hours before exertion
Trial: 10731304
Drug: Chronic treatment
RxNorm normalized name: Hongo Killer Treatment
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Chronic treatment with Nedocromil sodium for 2 and 4 weeks
Trial: 7594444
Drug: Sinorphan (100
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Sinorphan (100 mg twice a day)
Trial: 7594444
Drug: Combined therapy
RxNorm normalized name: REGN10933+REGN10987 combination therapy
DrugBank: Anti-SARS-CoV-2 REGN-COV2 (DB15691)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Combined therapy of Sinorphan and Captopril
Trial: 7594444
Drug: Sinorphan alone
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Sinorphan alone or in combination with Captopril
Trial: 7272867
Drug: Conventional therapy
RxNorm normalized name: Monistat Simple Therapy
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Conventional therapy only (Control)
Trial: 23453391
Drug: Ergocalciferol 50,000
RxNorm normalized name: ergocalciferol 50,000 intl units oral tablet
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Ergocalciferol 50,000 IU once weekly for 12 weeks
Trial: 21425568
Drug: Composite Sophora
RxNorm normalized name: Sophora pachycarpa whole extract
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Composite Sophora Colon‐soluble Capsules (CSCC) plus Etiasa simulated placebo for 8 weeks
Trial: 11730742
Drug: Crinone 8%
RxNorm normalized name: Crinone 8% Vaginal Gel
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Crinone 8% (90 mg once daily)
Trial: 10560985
Drug: IM progesterone
RxNorm normalized name: Progesterone
DrugBank: Progesterone (DB00396)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: IM progesterone (50 mg once daily)
Trial: 9164992
Drug: Acarbose (50-200
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Acarbose (50-200 mg, three times per day)
Trial: 8083699
Drug: Quinidine (250
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Quinidine (250 mg) capsules taken for 4 days before and 2 days after chemotherapy
Trial: 2769131
Drug: Iodophor cream
RxNorm normalized name: iodophors
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Iodophor cream
Trial: 2769131
Drug: Chlorhexidine cream
RxNorm normalized name: chlorhexidine Topical Cream
DrugBank: Chlorhexidine (DB00878)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Chlorhexidine cream
Trial: 239807
Drug: Lorazepam 1.33
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Lorazepam 1.33 mg intramuscularly
Trial: 239807
Drug: Lorazepam 4
RxNorm normalized name: lorazepam 4 MG/ML
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Lorazepam 4 mg intramuscularly
Trial: 1170
Drug: Pentobarbital 50
RxNorm normalized name: PENTobarbital 50 mg oral capsule
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Pentobarbital 50 mg
Trial: 239807
Drug: Pentobarbital 150
RxNorm normalized name: Pentobarbital
DrugBank: Pentobarbital (DB00312)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Pentobarbital 150 mg
Trial: 18308009
Drug: Oral testosterone
RxNorm normalized name: testosterone Oral Capsule
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Oral testosterone undecanoate (TU; 80 mg twice daily)
Trial: 11191009
Drug: Domperamol (fixed
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Domperamol (fixed combination of domperidone and paracetamol)
Trial: 8772902
Drug: Isoniazid 5
RxNorm normalized name: isoniazid 50 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Isoniazid 5 mg/kg
Trial: 1993561
Drug: Minoxidil gel
RxNorm normalized name: Minoxidil
DrugBank: Minoxidil (DB00350)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Minoxidil gel
Trial: 30261084
Drug: Omission of
RxNorm normalized name: OIL OF CAMPHOR
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Omission of ACEI therapy
Trial: 30261084
Drug: Continuation of
RxNorm normalized name: varenicline
DrugBank: Varenicline (DB01273)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Continuation of ACEI therapy
Trial: 24809233
Drug: Sublingual administration
RxNorm normalized name: polidocanol
DrugBank: Polidocanol (DB06811)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Sublingual administration of 3 mg tacrolimus powder for 15 min
Trial: 24809233
Drug: Rectal administration
RxNorm normalized name: polidocanol
DrugBank: Polidocanol (DB06811)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Rectal administration of 15 mg tacrolimus suppository
Trial: 24809233
Drug: Oral administration
RxNorm normalized name: polidocanol
DrugBank: Polidocanol (DB06811)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Oral administration of 7 mg tacrolimus capsules (Prograf)
Trial: 19329465
Drug: Periodontal therapy
RxNorm normalized name: Monistat Simple Therapy
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Periodontal therapy and oral hygiene instruction in the third trimester
Trial: 15766369
Drug: No periodontal
FDA approved: no
EMA approved: no
PMDA approved: no
Description: No periodontal treatment (Control)
Trial: 15177793
Drug: Imitation (concurrent
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Imitation (concurrent (CI) and delayed (DI))
Trial: 11779723
Drug: Montelukast 10
RxNorm normalized name: montelukast 10 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Montelukast 10 mg once daily for 4 weeks
Trial: 2564782
Drug: Atracurium (0.92‐0.98
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Atracurium (0.92‐0.98 mg kg‐1) administered by continuous infusion or intermittent bolus doses
Trial: 2564782
Drug: Vecuronium (0.16‐0.18
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Vecuronium (0.16‐0.18 mg kg‐1) administered by continuous infusion or intermittent bolus doses
Trial: 2564782
Drug: Control group
RxNorm normalized name: meningococcal group B vaccine Prefilled Syringe [Trumenba]
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Control group receiving no neuromuscular blocking drugs
Trial: 606784
Drug: All vaccine
RxNorm normalized name: All Clear
DrugBank: Ethanol (DB00898)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: All vaccine preparations
Trial: 26112148
Drug: Heating and
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Heating and cooling combination therapy (OCH-S100), 10 treatments (15 min each) over 4 weeks, consisting of five cycles of heating/cooling therapy (max: 45 °C, min: 15 °C).
Trial: 26112148
Drug: Sham therapy,
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Sham therapy, 10 treatments (15 min each) over 4 weeks, consisting of five cycles of sham therapy (max: 1 °C above skin temperature, min: 1 °C below skin temperature).
Trial: 16408206
Drug: rHEPO+G‐CSF (10,000
FDA approved: no
EMA approved: no
PMDA approved: no
Description: rHEPO+G‐CSF (10,000 IU rHEPO s.c. three times a week + 300 mug G‐CSF s.c. twice a week)
Trial: 16408206
Drug: rHEPO+G‐CSF
FDA approved: no
EMA approved: no
PMDA approved: no
Description: rHEPO+G‐CSF
Trial: 9250230
Drug: Intervention group
RxNorm normalized name: Streptococcus viridans group
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Intervention group (n = 141) received antibiotic-related suggestions from an infectious disease fellow and a clinical pharmacist.
Trial: 9250230
Drug: Control group
RxNorm normalized name: meningococcal group B vaccine Prefilled Syringe [Trumenba]
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Control group (n = 111) did not receive antibiotic-related suggestions.
Trial: 12079004
Drug: 150 mg
RxNorm normalized name: pectin 150 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 150 mg nizatidine
Trial: 1676392
Drug: 300 mg
RxNorm normalized name: rutin 300 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 300 mg nizatidine
Trial: 8099802
Drug: 600 mg
RxNorm normalized name: mesna 600 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 600 mg nizatidine
Trial: 1889143
Drug: 100 mg
RxNorm normalized name: urea 100 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 100 mg pirenzepine
Trial: 8099802
Drug: 300 mg
RxNorm normalized name: rutin 300 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 300 mg nizatidine plus 100 mg pirenzepine
Trial: 3332556
Drug: Sequential combination
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Sequential combination with progestagen
Trial: 23238504
Drug: Preoperative radiotherapy
RxNorm normalized name: povidone-iodine
DrugBank: Povidone-iodine (DB06812)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Preoperative radiotherapy (25 Gy in 5 fractions) and postoperative chemotherapy (5-fluorouracil and leucovorin)
Trial: 20564352
Drug: PEG‐IFN‐lambda at
FDA approved: no
EMA approved: no
PMDA approved: no
Description: PEG‐IFN‐lambda at 1.5 or 3.0 microg/kg administered every 2 weeks or weekly for 4 weeks (Part 1)
Trial: 20564352
Drug: Weekly doses
RxNorm normalized name: selinexor
DrugBank: Selinexor (DB11942)
FDA approved: yes
EMA approved: yes
PMDA approved: no
Description: Weekly doses of PEG‐IFN‐lambda ranging from 0.5 to 2.25 microg/kg in combination with ribavirin (RBV) for 4 weeks (Part 2)
Trial: 20564352
Drug: Weekly PEG‐IFN‐lambda
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Weekly PEG‐IFN‐lambda at 1.5 microg/kg in combination with RBV for 4 weeks (Part 3)
Trial: 12447009
Drug: 0.125% dextrin
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 0.125% dextrin sulfate (DS) gel
Trial: 550158
Drug: Indomethacin (prostaglandin
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Indomethacin (prostaglandin synthesis inhibitor)
Trial: 31488213
Drug: Iloprost 1
RxNorm normalized name: ILOPROST 100MCG/ML INJ,SOLN
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Iloprost 1 ng/kg/min and eptifibatide 0.5 μg/kg/min for 48 hours
Trial: 19736900
Drug: 40 mg
RxNorm normalized name: rutin 40 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 40 mg oxycodone administered intravenously over 2 minutes
Trial: 19736900
Drug: 40 mg
RxNorm normalized name: rutin 40 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 40 mg oxycodone administered intravenously over 15 minutes
Trial: 19736900
Drug: 0 mg
RxNorm normalized name: RNA 180 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 0 mg oxycodone administered intravenously
Trial: 3127965
Drug: Oxamniquine at
RxNorm normalized name: oxamniquine
DrugBank: Oxamniquine (DB01096)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Oxamniquine at 20 mg/kg
Trial: 3127965
Drug: Oxamniquine at
RxNorm normalized name: oxamniquine
DrugBank: Oxamniquine (DB01096)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Oxamniquine at 30 mg/kg